76471-08-4

Basic information

• Product Name: 4-(Pyridin-2-yloxy)aniline
• Synonyms: 4-(Pyridin-2-yloxy)aniline
• CAS NO: 76471-08-4
• Molecular Formula: C₁₁H₁₀N₂O
• Molecular Weight: 186.2099
• Mol File: 76471-08-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(Pyridin-2-yloxy)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Pyridin-2-yloxy)aniline(76471-08-4)
• EPA Substance Registry System: 4-(Pyridin-2-yloxy)aniline(76471-08-4)

Safety Data

• Hazardous Substances Data: 76471-08-4(Hazardous Substances Data)

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 142-08-5 2-hydroxypyridin 
• 372-48-5 2-fluoropyridine 
• 123-30-8 4-amino-phenol 
• 5029-67-4 2-iodopyridine 
• 109-04-6 2-bromo-pyridine 
• 4783-81-7 2-<(4-nitrophenyl)oxy>pyridine 

Downstream Products

• 1227173-85-4 N-(4-(pyridin-2-yloxy)phenyl)-1H-benzo[d]imidazol-2-amine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY

The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.

Discovery of 1,2,4-triazole-1,3-disulfonamides as dual inhibitors of mitochondrial complex II and complex III

Respiratory chain succinate-ubiquinone oxidoreductase (SQR or complex II) and ubihydroquinone-cytochrome (cyt) c oxidoreductase (cyt bc1 or complex III) have been demonstrated as the promising targets of numerous antibiotics and fungicides. As a continuation of our research work on the development of new fungicides, a series of 1,2,4-triazole-1,3-disulfonamide derivatives with dual functions targeting both SQR and cyt bc1 were designed and synthesized by coupling diverse diphenyl ether moieties with triazolesulfonamide units. These newly synthesized compounds were characterized by elemental analyses, 1H NMR and ESI-MS spectrometry. The in vitro assay indicated that most of the synthesized compounds displayed good inhibition against porcine succinate-cytochrome reductase (SCR) with IC50 values ranging from 3.2 to 81.8 μM, revealing much higher activity than that of the commercial control amisulbrom whose IC50 value is 93.0 μM. Further evaluation against the respective SQR and cyt bc1 indicated that most compounds exhibited SQR-inhibiting activity as well as cyt bc1-inhibiting activity, but the inhibition potency against SQR is much higher than that against cyt bc1, showing that the SCR inhibition might be contributed greatly by the SQR inhibition. The further antibacterial evaluation against Xanthomonas oryzae pv. oryzae revealed that four compounds showed excellent potency at the concentration of 20 μg mL-1. In particular, compounds 6h and 6j exhibited much better antibacterial activity than the commercial control bismerthiazol in terms of their EC50. Impressively, 6j has an EC90 of 33.62 μg mL-1, more than 10-fold higher than that of bismerthiazol.

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.